ABCB5+ MSCs
Diabetic foot ulcers (DFU)
Key Facts
About RHEACELL
RHEACELL is a German biotech leader advancing a late-stage pipeline of allogeneic, off-the-shelf stem cell therapies based on its proprietary ABCB5+ mesenchymal stromal cell platform. The company's lead program targets recessive dystrophic epidermolysis bullosa (RDEB) in a pivotal Phase 3 trial and already holds national marketing authorization in Germany for chronic venous ulcers (AMESANAR®). With over 20 years of foundational research, in-house GMP manufacturing, a strong IP portfolio, and strategic partnerships like the 2025 alliance with AOP Health, RHEACELL is positioned to address significant orphan and rare disease markets through its immunomodulatory and tissue-regenerative therapeutics.
View full company profileAbout RHEACELL
RHEACELL is a German biotech leader advancing a late-stage pipeline of allogeneic, off-the-shelf stem cell therapies based on its proprietary ABCB5+ mesenchymal stromal cell platform. The company's lead program targets recessive dystrophic epidermolysis bullosa (RDEB) in a pivotal Phase 3 trial and already holds national marketing authorization in Germany for chronic venous ulcers (AMESANAR®). With over 20 years of foundational research, in-house GMP manufacturing, a strong IP portfolio, and strategic partnerships like the 2025 alliance with AOP Health, RHEACELL is positioned to address significant orphan and rare disease markets through its immunomodulatory and tissue-regenerative therapeutics.
View full company profileTherapeutic Areas
Other Diabetic foot ulcers (DFU) Drugs
| Drug | Company | Phase |
|---|---|---|
| Intralesional rhEGF (Heberprot-P related) | Discovery Therapeutics Caribe | Phase 3 |
| Nanordica® Advanced Antibacterial Wound Dressing | Nanordica Medical | Phase 2/3 |
| DeepView Wound Imaging System | Spectral AI | Unknown |
| ORBCEL™ for Diabetic Foot Ulcers | Orbsen Therapeutics | Pre-clinical/Research |